Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk

[1] Lewington S(2007)Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 1829-1839

[2] Whitlock G(2002)Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-1913

[3] Clarke R(2005)Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins Lancet 366 1267-1278

[4] Lewington S(2000)Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 145-153

[5] Clarke R(2001)Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack Lancet 358 1033-1041

[6] Qizilbash N(2002)Risk factor thresholds: their existence under scrutiny Bmj 324 1570-1576

[7] Peto R(2005)Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk Lancet 365 434-441

[8] Collins R(2008)Cardiovascular risk prediction: are we there yet? Heart 94 1-3

[9] Baigent C(2004)Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Ann Intern Med 141 413-420

[10] Keech A(2004)Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Ann Intern Med 141 421-431

[1] Lewington S(2007)Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 1829-1839

[2] Whitlock G(2002)Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-1913

[3] Clarke R(2005)Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins Lancet 366 1267-1278

[4] Lewington S(2000)Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 145-153

[5] Clarke R(2001)Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack Lancet 358 1033-1041

[6] Qizilbash N(2002)Risk factor thresholds: their existence under scrutiny Bmj 324 1570-1576

[7] Peto R(2005)Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk Lancet 365 434-441

[8] Collins R(2008)Cardiovascular risk prediction: are we there yet? Heart 94 1-3

[9] Baigent C(2004)Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Ann Intern Med 141 413-420

[10] Keech A(2004)Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Ann Intern Med 141 421-431